Cargando…
Antibodies and Vaccines Target RBD of SARS-CoV-2
The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vi...
Autores principales: | Min, Long, Sun, Qiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100443/ https://www.ncbi.nlm.nih.gov/pubmed/33968996 http://dx.doi.org/10.3389/fmolb.2021.671633 |
Ejemplares similares
-
In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine
por: Masoomi Nomandan, Seyedeh Zeinab, et al.
Publicado: (2022) -
Antigen–Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD
por: Fung, Kit-Man, et al.
Publicado: (2022) -
Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
por: Hoter, Abdullah, et al.
Publicado: (2022) -
In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19
por: Teli, Divya M., et al.
Publicado: (2021) -
Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants
por: Gelbach, Adrianne L., et al.
Publicado: (2022)